RD Biomed lands Jordanian export deal

RD Biomed lands Jordanian export deal

Hull-based medical technology company RD Biomed has signed a distribution deal with pharmaceutical distributor Nebras Jordan to launch its reflux diagnostic device Peptest in Jordan.

Peptest is an accurate, painless and inexpensive saliva test that tells you conclusively if you have reflux. It measures the presence of the digestive enzyme pepsin in saliva, which is a reliable marker for the reflux of gastric juice.

Nebras Jordan has registered Peptest with the country’s regulatory body Jordan Food and Drug Administration (JFDA), secured distribution channels with four laboratories and arranged insurance. It will now work closely with doctors across Jordan to demonstrate the benefits of Peptest.

Prof Peter Dettmar of RD Biomed said: “We are thrilled to appoint Nebras Jordan as our exclusive distributor in Jordan. The Jordan health market is the leader in the area for new technologies which makes it a fantastic place to launch Peptest and pioneer the technology in the MENA region.”

Dr Feras Zuriekat in Jordan, said: “We are delighted to have Peptest in Jordan; reflux is a disease on the rise worldwide, it affects the quality of life of patients and could have serious consequences, such as increased risk of oesophageal and laryngeal cancers.

“Managing reflux can be challenging and Peptest is a very useful non-invasive tool that will help clinicians to diagnose and follow up patients."

Medical professionals in Jordan can order Peptest via Nebras Jordan who will locate the nearest laboratory where Peptest is available.

Peptest is now available in more than 20 countries including China, India, Spain, Italy, Ireland and the UK.